Back to results
US 2006/0222657 A1Published application
Polypeptide transduction and fusogenic peptides
OwnerSteven Dowdy, Jehangir Wadiainventors
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
OwnerSteven Dowdy, Jehangir Wadiainventors
Estimating the term…
Due to the barrier imposed by the cell membrane, delivery of macromolecules in excess of 500 Daltons directly into cells remains problematic. However, proteins, which have been evolutionarily selected to perform specific functions, are therefore an attractive therapeutic agent to treat a variety of human diseases. In practice, the direct intracellular delivery of these proteins has, until recently, been difficult to achieve due primarily to the bioavailability barrier of the plasma membrane, which effectively prevents the uptake of the majority of peptides and proteins by limiting their passive entry. However, recent work using small cationic peptides, termed protein transduction domains (PTDs), derived from polynucleotide binding proteins, such as HIV TAT protein or the Drosophila transcription factor Antp. or synthetic poly-Arginine, have now been shown to deliver a myriad of molecules, including synthetic small molecules, peptides and proteins, into animal models in vivo.
A composition comprising:
A kit comprising a vessel or vessels containing
An article of manufacture comprising a vessel containing
An article of manufacture comprising, packaged together:
A method of introducing a heterologous polypeptide into a target cell, the method comprising contacting the cell with a composition comprising:
A fusion polypeptide comprising a protein transduction domain and a fusogenic domain.
Dependencies are inferred from the claim text.